Photodynamic therapy (PDT) is a relatively safe way for disease diagnosis and treatment that is based on light and photosensitizers. LS-HB is a promising photosensitizer with a light absorption peak of 660 nm. Aims: The present study aimed to investigate the anticancer effects of LS-HB-PDT on hepatocellular carcinoma and its underlying molecular mechanism. Methods: In the present study, the MTT assay and xenograft tumor model experiment were used to evaluate its anticancer effects as well as its dark toxicity in hepatocellular carcinoma in vitro and in vivo. Reactive oxygen species assay kit was utilized to detect the reactive oxygen species production induced by LS-HB-PDT. Results: In vitro, the MTT assay results revealed that LS-HB-PDT exhibited significant cytotoxic effects both in a drug- and light dose-dependent manner. The IC(50 )of LS-HB-PDT on hepatocellular carcinoma cells was 2.685 mu g/ml. However, no dark cytotoxicity was observed at the LS-HB concentrations of 0-50 mu g/ml, and no light-induced cytotoxicity was observed at the light (660 nm) dosages of 0-40 J/cm(2). Furthermore, reactive oxygen species could be induced after LS-HB-PDT in a drug- and light dose-dependent manner. In vivo experiment, the tumor inhibition ratio of tumor-bearing nude mice following LS-HB-PDT was enhanced with the drug and light dose increasing. Notably, tumors in 60.0% of mice disappeared after LS-HB-PDT (2 mg/kg; 100 J/cm(2)), and the tumor inhibition ratio reached 92.3%. Furthermore, the histological results revealed necrosis and thrombus in tumor tissue caused by LS-HB-PDT, which were not observed in the control, drug alone and light alone groups of mice. Conclusions: The present study indicated that LS-HB was a promising photosensitizer with excellent anticancer effects and low side effects. LS-HB-PDT induced reactive oxygen species damage in the cells directly and destroyed tumor blood vessels, thus leading to tumor tissue necrosis.

As a novel co-receptor for vascular endothelial growth factor (VEGF), neuropilin receptor type-1 (NRP-1) is overexpressed in several cancers and metastases, and serves as an attractive target for cancer molecular imaging and therapy. Previous single photon emission computerized tomography (SPECT) studies demonstrated that the small NRP-1-targeting peptides 99mTc-MA-ATWLPPR and 99mTc-CK3 showed poor tumor imaging quality, because of their rapid blood clearance and very low tumor uptake. Compared with small peptides, monoclonal antibodies (mAbs) can improve imaging of NRP-1-expression, due to their high affinity, specificity and slow extraction. A6-11-26 is a novel monoclonal antibody against NRP-1 b1b2 domain that exhibits inhibition of tumor growth in NPR-1-expressing preclinical models. The aim of the present study was to develop the 131I-labeled anti-NRP-1 monoclonal antibody A6-11-26 as a SPECT probe for imaging of NRP-1-positive tumor. An anti-NRP-1 monoclonal antibody (A6-11-26) was produced by hybridomas and was labeled with iodine-131 by the iodogen method. In vitro, the radiolabeling efficiency, radiochemical purity, immunoreactive fraction and stability were assessed. Binding affinity and specificity of 131I‑A6-11-26 to NRP-1 were evaluated using human glioblastoma U87MG cells. In vivo, biodistribution and SPECT/CT studies were conducted on mice bearing U87MG xenografts after the injection of 131I-A6-11-26 with or without co-injection of unlabeled A6-11-26 antibody. A6-11-26 was generated successfully by hybridoma with high purity (>95%) and was labeled with iodine-131 within 60 min with high labelling efficiency (95.46±3.34%), radiochemical purity (98.23±1.41%). 131I-A6-11-26 retained its immunoreactivity and also displayed excellent stability in mouse serum and PBS solution during 1 to 96 h. Cell uptake assays showed high NRP-1-specific uptake (15.80±1.30% applied activity at 6 h) in U87MG cells. 131I-A6-11-26 bound to NRP-1 with low nanomolar affinity (KD=1.67±0.14 nM) in U87MG cells. In vivo, biodistribution study demonstrated targeting of U87MG glioma xenografts was NRP-1 specific. The tumor uptake was 6.00±1.24%ID/g at 24 h, and the tumor to muscle ratio was 3.20±0.30 at 24 h, and reached the highest level of 6.13±0.24 at 120 h after injection. SPECT imaging studies revealed that 131I-A6-11-26 could clearly identify U87MG tumors with good contrast, especially at 72-120 h after injection. The present study demonstrates that 131I-A6-11-26 is capable of detecting lesions in an NRP-1-expressing tumor with high target selectivity, and may offer a promising SPECT agent for NRP-1 expression positive tumor and encourage further investigation.

OBJECTIVES:It has been reported that vascular plugging has become a therapeutic alternative to coil embolization in certain cases that require occlusion. However, the use of a relatively large and rigid delivery sheath may be a limiting factor in vascular plug use. In this study, we aimed to determine the safety and efficacy of a novel transcatheter occlusion device with unique design and delivery system in a pig model. METHODS:The Cera vascular plug was delivered and deployed through the FuStar steerable introducer sheath, which can control tip direction during advancement. Twelve pigs were randomized to undergo an embolization procedure in which the Cera vascular plug was implanted into the left internal iliac artery (IIA) with the FuStar steerable introducer (n = 6) or a control introducer sheath. Another eight pigs were assigned to undergo an embolization procedure in which the test device was implanted into either the splenic artery (SA, n = 4) or the lower segmental branch of left renal artery (LRA, n = 4). Angiography and pathological examinations were performed to evaluate the outcomes. RESULTS:A total of 20 target vessels were embolized with a total of 22 test plugs. Compared with the control introducer, plug embolization through the FuStar steerable introducer was associated with shorter fluoroscopy time (21.50 ± 3.62 vs. 28.33 ± 2.16 min, P = 0.003) and less contrast medium (129.17 ± 22.68 vs. 162.50 ± 13.69 mL, P = 0.012). At the 2-month follow-up, angiography and pathological examinations did not show any evidence of migration, and persistent occlusion was observed in 18 of the 20 target vessels. Organ ischemia occurred when plugs were deployed within the lower segmental branch of the LRA. CONCLUSION:This novel device is suitable for therapeutic vascular embolization with the use of flexible delivery systems. The different outcomes of SA and LRA plugging suggested that the occluding device should be placed within the appropriate portion of the target vessel to allow the development of collateralization.

Neuropilin-1 (NRP-1) is a nontyrosine kinase coreceptor for semaphorin 3A and the vascular endothelial growth factor involved in tumor angiogenesis, growth, and metastasis and is regarded as a promising target for cancer therapy. In the present study, we investigated the effects of an anti-NRP-1 monoclonal antibody (mAb) that we generated for MCF7 breast cancer cellular adhesion studies. MTT, colony formation, and adhesion assays showed that our anti-NRP-1 mAb dose-dependently inhibited MCF7 proliferation and fibronectin adhesion, leading to a rounded cellular morphology. Further, rhodamine phalloidin stain revealed that fibronectin-dependent formation of actin stress fibers was inhibited by anti-NRP-1 mAb. Immunoprecipitation and western blot showed that anti-NRP-1 mAb treatment inhibited the formation of NRP-1-α5β1 integrin complexes and suppressed the phosphorylation of focal adhesion kinase and p130cas in MCF7 cells. These findings contribute to further understanding the NRP-1 function in cell adhesion and tumor metastasis. Moreover, our anti-NRP-1 mAb is a prospective drug candidate for tumor treatment.

Naked2 (NKD2) is a member of the Naked family and negatively regulates canonical Wnt signaling. NKD2 may play a role in embryo development and tumor formation by affecting Wnt signaling. In the present study, we describe the establishment of a monoclonal antibody against NKD2 (anti-NKD2 MAb) through the hybridoma method. The purified anti-NKD2 MAb measured a titer of 2.56 × 10(5) against NKD2 by indirect ELISA. Western blot analysis, immunoprecipitation, and confocal microscope showed that the anti-NKD2 MAb can specifically combine NKD2 protein in SW480 and LOVO cells. Competitive inhibition assays of Western blot and indirect ELISA showed that the anti-NKD2 MAb can be blocked with NKD2(1-217) protein. The anti-NKD2 MAb would be helpful for further studies on the structure activity relationship, protein detecting, and cell-signaling pathway of NKD2.

The goal of this study was to develop novel embolic nanoparticles for targeted tumor therapy with dual targeting: magnetic field-guided and peptide-directed targeting. The embolic nanoparticles SP5.2/tTF-OCMCs-SPIO-NPs were prepared by surface-modifying of superparamagnetic iron oxide nanoparticles (SPIO-NPs) with o-carboxymethylchitosans (OCMCs) and SP5.2/tTF (SP5.2: a peptide binding to VEGFR-1; tTF: truncated tissue factor) to improve their stability and to target over-expressing VEGFR-1 cells. The physicochemical characterization results showed that the OCMCs-SPIO-NPs have a spherical or ellipsoidal morphology with an average diameter of 10–20nm. And they possess magnetism with a saturation magnetization of 66.1emu/g, negligible coercivity and remanence at room temperature. In addition, the confocal microscopy, Prussian blue staining and FX activation analysis respectively demonstrated the peptide-directed targeting, magnetic field-guided targeted and blood coagulation activity of the SP5.2/tTF-OCMCs-SPIO-NPs. These properties separately belong to SP5.2, Fe3O4 and tTF moieties of the SP5.2/tTF-OCMCs-SPIO-NPs. Thus these SP5.2/tTF-OCMCs-SPIO-NPs with double-targeting function should have a potential application in embolization therapy of tumor blood vessels.

Protein tyrosine phosphatase 1B (PTP1B), a member of the protein tyrosine phosphatase (PTP) family, plays a crucial role in metabolic signaling, with insulin and leptin signaling being well studied. New evidence indicates that PTP1B is also involved in cancer. In the present study, we report on the establishment of a monoclonal antibody specific for catalytic domain of PTP1B (PTP1Bc) generated through the hybridoma method. The monoclonal antibody is measured to have a titer of 4.1×10(6) against PTP1Bc in indirect ELISA. Western blot and immunofluorescent analyses indicated that this antibody can specifically combine native PTP1B in MDA-MB-231 and MDA-MB-453 cells. This monoclonal antibody against PTP1Bc can help enhance the understanding of PTP1B-related physiological and pathological mechanisms and may act as a therapeutic agent for diabetes, obesity, and cancer in the future.

Neuropilin-1 is a member of the neuropilins family protein, which contains a large extracellular domain (a1a2, b1b2 and c), a single transmembrane domain, and a short cytoplasmic tail. NRP-1 plays a critical role in angiogenesis and stimulates endothelial cell division and migration by binding VEGF(165) with b1b2 domain. In the present study, we report the establishment of a monoclonal antibody (A6-26-11-26 clone) specific for NRP-1 b1b2 through hybridoma method. Western blot analysis indicates that our NRP-1 b1b2 MAb can combine both NRP-1 b1b2 and NRP-1 originated from tumor cells. This monoclonal antibody against NRP-1 b1b2 will be useful in the further development of cancer target strategy.

Objective: To evaluate the effect of radiation on osseointegration and the bone density adjacent to implant. Methods: 16 rabbits, implanted with one pieces of pure Ti implants in each side tibias, were divided into 2 groups randomly. Experiment group received radiation after the implant wound healed. All rabbits were sacrificed at 4,8,16,24 weeks postoperationaly. The specimen were observed by gross examination, X-ray, histological examination, ground section of bone with implant, energy dispersion X-ray analysis. Results: At 4 weeks, the bone density adjacent to implant and osseointegration of the simple irradiation group was lower than that of control group(P0.05). At 16 weeks, there were no significant difference between two groups. Osseointegration in experimental groups started at the 8th week, but in control group it started at 4th week. Conclusion: Radiation shows considerable negative effect on osseointegration to implants in a short-term, but it's not obvious after 16 weeks.

OBJECTIVETo evaluate the effect of tissue engineering bone in maxillary sinus lifting.METHODSThe marrow stromal stem cells of dog were cultured in DMEM containing 100 m1/L fetal bovine serum and induced to differentiate to osteoblasts, which were then inoculated together with Bio-Oss for 5 days. Sixteen dog's bilateral maxillary sinus were elevated. One side was grafted with a compound of BMSC and Bio-Oss and the other side grafted with Bio-Oss alone. The samples were studied by gross, CT, histomorphology and histomorphometrical analysis at the 30th, 90th day after the operation. t-test was used for statistical analysis.RESULTSIn gross view and CT, new bone formation was observed in all maxillary sinus after 30 and 90 days respectively. Histomorphometrical analysis showed much more new callus in BMSC-Bio-Oss group than in Bio-Oss group (P < 0.05).CONCLUSIONSA better effect of new bone formation could be obtained with tissue engineered bone in maxillary sinus lifting.

PURPOSE:To evaluate the effect of radiation and osteogenic growth peptide(OGP) on the bone density adjacent to the implants.METHODS:24 rabbits underwent 48 implants placed in the tibia, then the rabbits were divided into one control group and two experimental groups randomly. Rabbits in one of the experimental groups were injected with OGP Sol, rabbits in the other groups were injected with normal saline; Then rabbits in the two experimental groups received radiation after the implant wound healed. 12 rabbits were sacrificed at 4 weeks and 16 weeks respectively. The samples were observed with gross, X-ray, histological examination. The data was analysed for Dunnett t test using SPSS13.0 software package.RESULTS:At 4 weeks, the bone density adjacent to the implant of the simple irradiation group was significantly less than that of the control group (P<0.05), while the difference was not significant between the irradiation and OGP group and the control group. At 16 weeks, the difference among the three groups wasn't significant.CONCLUSIONS:Radiation has considerable adverse effect on osteogenesis adjacent to the implants, while systemically administering OGP plays significant roles in the osteogensis of the irradiated rabbit tibia.

目的观察Vitapex糊剂治疗慢性根尖周炎的疗效。方法慢性根尖周炎患者131例,常规根管预备完善后,分别予以Vitapex糊剂和普通根充糊剂加牙胶尖法充填根管,观察两组疗效和根充后反应的差异。结果Vitapex糊剂加牙胶尖根充组的术后急性反应率明显小于普通根充糊剂加牙胶尖根充组(P<0.05),但1年后复查两组间成功率差异无统计学意义(P<0.05)。结论Vitapex糊剂根充后的急性反应率比普通根充糊剂小。

发生在口腔颌面部的转移癌较为少见,现将我们在2003年治疗的2例报告如下,并复习相关文献.

目的:观察曲安缩松加枸橼酸钾铋联合治疗口腔黏膜扁平苔藓(OLP)的临床疗效。方法:57例OLP患者随机分为治疗组和对照组,治疗组以曲安缩松加2%利多卡因作病损黏膜下多点注射,1次/周,同时口服三钾二枸橼酸钾铋胶囊110 mg,4次/d×60 d。对照组口服磷酸氯喹0.125 g/次,2次/d×60 d。结果:治疗组痊愈率78%,总有效率97%。对照组痊愈率为0,总有效率57%,两组间痊愈率及总有效率有显著性差异,P<0.05。结论:曲安缩松加枸橼酸钾铋剂治疗OLP疗效较好,以上提示OLP与慢性胃炎在临床上密切相关。

Objective To analyze the common complication and their prevention after repaired with metal ceramic restoration retrospectively.Methods 286 cases with 462 teeth were enrolled and repaired with metal ceramic restoration in our hospital in recent two years with at least half-year follow-up.The out come and the common complications of the cases were retrospectively evaluated.Results The patients were satisfied with 427 of the total 462 teeth,and not satisfied with 35 teeth which including 6 ceramic collapse,6 crown loose,4 teeth break,3 front teeth gingival color change,12 repaired teeth gingivitis,3 teeth food impaction,and 1 secondary carried on root.Conclusion The clinical application of metal ceramic teeth repair could be satisfied.The common complications after metal ceramic teeth repair include ceramic collapse,tooth loose,tooth break,food impaction,gingivitis,result of unsuitable design and gum color change.The total complications were low and could be avoided by precise design and careful performance.

ObjectiveTo evaluate the clinical effects of Replace implant prosthesis with nonsubmerged surgery mothed.MethodsOne hundred Replace implants were placed into maxillary and mandibular used nonsubmerged surgery,After four to six months for maxillary and three to four months for mandible,implant restoration was completed with Porcelain-fused-to metal crown(golden Alloy).Implant success rate,prosthesis success rate and gingival state sunounding the implant were followed-up for three years.ResultsSuccess rate of implant and prosthesis were 100%.Perio-implantitis was nonobserved in all patients.ConclusionThe clinical effects of Replace implant prosthesis used nonsubmerged surgery mothed are practical and reliable.

牵引延长骨生成技术(牵张成骨术)应用于颌面外科领域始于20世纪90年代.应用该技术治疗颞下颌关节骨性强直国内仅有少量报道.现报告1例. 1.临床资料

目的:通过动物实验及临床研究评价钛板颌骨内固定系统的临床应用效果.方法:实验测试了内固定系统的机械性能和组织反应性.临床对167例颌骨骨折病例应用钛板颌骨内固定治疗,观察咬牙合关系、咀嚼功能、开口度、面部畸形等恢复情况.结果:微型接骨板桡曲强度偏低、钛板、钛钉表面耐磨性差.167例临床病例治疗效果可靠.结论:该固定系统设计合理,应用于颌骨骨折的治疗疗效可靠.